The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice

• Published in: International journal of molecular sciences Vol. 19; no. 1; p. 137
• Main Authors: Wang, Dong, Luo, Yuhuan, Wang, Xiaoxin, Orlicky, David, Myakala, Komuraiah, Yang, Pengyuan, Levi, Moshe
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 03.01.2018; MDPI
• Subjects: Animals; Antidiabetics; Benzhydryl Compounds - pharmacology; Benzhydryl Compounds - therapeutic use; Blood Glucose - metabolism; Diet, Western; Glucosides - pharmacology; Glucosides - therapeutic use; Inflammation - complications; Inflammation - pathology; Insulin Resistance; Kidney Diseases - blood; Kidney Diseases - complications; Kidney Diseases - drug therapy; Kidney Diseases - prevention & control; Kidney Glomerulus - drug effects; Kidney Glomerulus - pathology; Lipids - blood; Liver - drug effects; Liver - injuries; Liver - pathology; Liver Cirrhosis - complications; Liver Cirrhosis - drug therapy; Liver Cirrhosis - pathology; Liver diseases; Liver Diseases - blood; Liver Diseases - complications; Liver Diseases - drug therapy; Liver Diseases - prevention & control; Male; Mice, Inbred C57BL; Mice, Obese; Microscopy; Obesity; Obesity - blood; Obesity - drug therapy; Oxidative Stress - drug effects; Rodents; Sodium-Glucose Transporter 2 Inhibitors; Weight Gain - drug effects; fibrosis; SGLT2; inflammation; lipid; dapagliflozin; obesity

Obesity and obesity related kidney and liver disease have become more prevalent over the past few decades, especially in the western world. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic agents with promising effects on cardiovascular and renal function. Given SGLT...